Abstract: Objective: To assess the efficacy and safety of prophylactic quadrivalent human papillomavirus （HPV） vaccine in preventing cervical cancer and infection and diseases associated with vaccine-type HPV.
Methods: The Cochrane library, MEDLINE, EMBASE, NGC, CBM were searched, the randomised controlled trials （RCTs） about the efficacy and safety of prophylactic quadrivalent HPV vaccine were included. Two reviewers independently abstracted the data and assessed the quality. The data were input and analyzed by RevMan 4.2 software. Results: Five RCTs involving 23, 617 women met the inclusion criteria, meta-analysis showed that prophylactic HPV vaccination was associated with a significant reduction in the frequency of grade2 or 3 cervical intraepithelial neoplasia, adenocarcinoma in situ, grade2 or 3 vulvar intraepithelial neoplasia or vaginal intraepithelial neoplasia and genital warts caused by vaccine-type HPV strains compared with those in the control groups. The major adverse events were minor. The incidence of serious adverse events was balanced between the vaccine and control groups. Conclusion: Prophylactic HPV vaccination was efficacious and safe in preventing cervical cancer and genital diseases associated with vaccine-type HPV.

Key words: Quadrivalent human papillomavirus vaccination, Prevent, Cervical neoplasm, Meta-analysis